The next phase of clinical development for the CF10 prodrug to treat cystinosis has been announced. The Cystinosis Foundation UK will receive £3.9 million in research funding to conduct the CF10 clinical trial aimed at improving life with cystinosis. To learn more about this development, visit their website.
If you attended the 2025 CRN Family Conference you’ll recall the session, “Addressing the problems with cysteamine treatment: An update on the development of CF10.” You can access that recording now on the CRN’s YouTube channel.